Merck KGaA
Operates as a science and technology company providing life sciences products and services, healthcare pharmaceuticals across multiple therapeutic areas, and advanced materials for semiconductor manufacturing.
As of Oct 15, 2026
Summary
Merck KGaA is a German healthcare company trading on XETRA with a market capitalisation of €59.8 billion. The stock is displaying a bullish technical bias, having climbed 8.4% over the past month and 24.3% over the past year, with today's session showing a gain of 3.1% to €141.90.
Price history
As of Oct 14, 2026
Performance
+0.95%
+1.25%
+8.40%
+4.11%
+18.06%
+24.30%
As of Oct 14, 2026
Technical indicators
- 60.9
- 0.59Bullish
- 50: 136.89 · 200: 127.46Bullish
- €135.30 / €142.60
Technical Bias
Bullish lean
The technical picture for Merck KGaA leans bullish overall: momentum has turned positive via MACD, the 50-day moving average sits above the 200-day average confirming an uptrend, and the stock trades near recent resistance at €142.60. This is a derived technical read from the indicator tally—not a recommendation.
A transparent read of the indicators below — not a prediction or recommendation.
As of Oct 14, 2026
Fundamentals
- €59.8B
- 25.53
- €5.39
- 11.21%
- +3.4%
- €2.35B
- 0.79
- €98.72 – €148.80
- 1.57%
- Apr 27, 2026
- Nov 12, 2026 (27 days)
As of Oct 16, 2026
Upcoming catalysts
- Earnings report
As of Oct 16, 2026
Latest news
As of Oct 16, 2026
MonkeyTrade's Take on Merck KGaA
Short-term outlook
Merck KGaA's short-term setup leans bullish: price sits above both the 50-day (€136.89) and 200-day (€127.46) averages, MACD confirms upward momentum, and the stock is up 8.4% over the past month. RSI at 60.9 still leaves room before overbought territory. A push through €142.60 resistance would reinforce the trend, while a slip below €135.30 support would call it into question. No earnings catalyst is imminent, with the next report not due until November 12, 2026.
Medium-term outlook
Merck KGaA's revenue growth of 3.4% and an 11.2% profit margin point to steady, if unspectacular, fundamentals, while the bullish technical lean suggests the market is already leaning constructive on the next few quarters. With a 25.53 P/E, shares aren't cheap, so the medium-term case rests on margins holding up; a slip in profitability would be the key signal to revisit this view.
Key risks
- Merck KGaA sits across electronics, healthcare and life sciences, so a slowdown in any one segment, such as semiconductor demand cited in the EMD Electronics survey, can weigh on overall results.
- Revenue growth of only 3.4% year-on-year alongside a profit margin of 11.2% suggests limited room for error if cost pressures or competitive dynamics intensify.
- The continuous bioprocessing market is forecast to grow at a 21.5% CAGR, putting Merck KGaA in direct competition with larger or more specialised players like Thermo Fisher, Danaher, Sartorius and Lonza.
- With shares trading at €141.90, close to the 52-week high of €148.80, and a price-to-earnings ratio of 25.53, the stock may already reflect a
About Merck KGaA
Merck KGaA is a German healthcare company operating in the specialty and generic drug manufacturing space, trading on the XETRA exchange under the symbol MRK. With a market capitalisation of €59.8 billion, it ranks among the more substantial names in Europe's pharmaceutical sector, reflecting a scale that places it firmly among established players in the drug manufacturing industry.
The company's key figures give a sense of how the market currently views it. A price-to-earnings ratio of 25.53 suggests investors are paying a notable premium relative to earnings, often a sign of expectations for steady or growing profitability. Meanwhile, a dividend yield of +1.6% offers shareholders a modest income stream alongside any share price movement, a common feature among healthcare companies balancing reinvestment in research with returns to investors.
How to trade Merck KGaA
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.